Any current/future capex/capital investment/strategic investment?

No substantial capex is planned immediately; only small capexes are expected in FY25. Focus currently is on improving utilization of existing capacity rather than large new investments. A previous large capex was done last year to create infrastructure supporting up to 60-70 million devices annually. Installed equipment currently supports 25-30 million devices per year; additional machinery will be added as approvals and scale-up occur. Future additional capex of around $15-20 million may be required to expand capacity from 30 million to 70 million devices, but this is not expected within the

Future growth expectations in sales/revenue/volumes?

Pharma segment expected to grow at 50%-60% in the current year (FY '25). Overall volume of pens/devices anticipated to increase from ~11 million in FY '24 to around 17-18 million in FY '25, reflecting 15%-16% growth. Capacity utilization currently around 40%, expected to increase as new business scales up. Plans to ramp up pen/device volumes gradually with approvals on proprietary platforms like Teriparatide and Liraglutide anticipated in FY '25. Additional capex of $15-$20 million planned over the next 6-7 years to expand capacity from current 25-30 million devices per year to ~60-70

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects margin improvement over the next 2-3 years driven by higher pharma revenues and more value-added products (Page 9). EBITDA margin improved to 19.2% in FY24, up 350 basis points YoY; PAT margin improved 310 basis points to 8.9% (Page 4). Pharma segment revenue grew 87% in FY24, signaling strong growth potential (Page 4). Capacity utilization currently at 40%, expected to increase in coming years, supporting volume growth (Page 4, 16). Healthcare/pharma segment expected to grow 50%-60% in the current year (Page 8-9). Pen volumes to grow at 15%-16% annually, with potential inc

Current/ Expected Orderbook/ Pending Orders?

Total ongoing projects across all molecules: approximately 20 to 23. Added 7 confirmed contracts in the recent year (4 earlier plus 3 more in Q4). Focus on regulated markets with approvals expected, particularly for Teriparatide and Liraglutide pens. Expecting commercial supplies for Teriparatide and Liraglutide pens in the current year. Auto-injector projects account for 4 out of the total projects; remainder are pen injectors. Pipeline for new contracts remains strong with ongoing bidding for new business. Capacity utilization currently ~40%, expected to increase as new business ramps up. Ex

Any current/future new fundraising through debt or equity?

There is no expectation for significant new fundraising through debt or equity in the near term. The company has already made a substantial capex investment last year, creating infrastructure to handle production capacity up to 60-70 million devices annually. Additional capex of $15-20 million may be needed to scale from 25-30 million to 70 million devices, but this is planned over the next 6-7 years, not the next 2-3 years. The management does not foresee the need for large-scale fundraising (e.g., $50-100 million) for semaglutide or other programs. The focus is on improving capacity utilizat

IN US

Sale is live|00:00:00left today

Shaily Engineering Plastics LtdQ1 FY24Consumer Durables

Shaily Engineering Plastics Ltd Q1 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,850P/E: 89.5Market Cap: ₹12.7K CrSector: Consumer Durables

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

Order

Yes

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Pharma segment expected to grow at 50%-60% in the current year (FY '25).
→Overall volume of pens/devices anticipated to increase from ~11 million in FY '24 to around 17-18 million in FY '25, reflecting 15%-16% growth.
→Capacity utilization currently around 40%, expected to increase as new business scales up.
→Plans to ramp up pen/device volumes gradually with approvals on proprietary platforms like Teriparatide and Liraglutide anticipated in FY '25.
→Additional capex of $15-$20 million planned over the next 6-7 years to expand capacity from current 25-30 million devices per year to ~60-70 million.
→Revenue growth expected from increasing proportion of proprietary devices (currently shifting from 10% to ~30-40% of value).
→Consumer segment faced a degrowth of ~4% due to raw material pass-through and lower toy sales but base business expected to grow 12%-15%.
→Shaily UK revenue to be back-ended with more growth expected in H2 FY '25.

Margin guidance

Category 3

→The company expects margin improvement over the next 2-3 years driven by higher pharma revenues and more value-added products (Page 9).
→EBITDA margin improved to 19.2% in FY24, up 350 basis points YoY; PAT margin improved 310 basis points to 8.9% (Page 4).
→Pharma segment revenue grew 87% in FY24, signaling strong growth potential (Page 4).
→Capacity utilization currently at 40%, expected to increase in coming years, supporting volume growth (Page 4, 16).
→Healthcare/pharma segment expected to grow 50%-60% in the current year (Page 8-9).
→Pen volumes to grow at 15%-16% annually, with potential increase from 11-12 million devices to 17-18 million in FY25 (Page 14).
→No substantial capex planned next 2-3 years; expansion will be via better utilization and incremental investments (Page 9, 16).
→EBITDA margin reported around 20%-21% consistently in recent quarters with expectations to improve gradually (Page 9).

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no expectation for significant new fundraising through debt or equity in the near term.
→The company has already made a substantial capex investment last year, creating infrastructure to handle production capacity up to 60-70 million devices annually.
→Additional capex of $15-20 million may be needed to scale from 25-30 million to 70 million devices, but this is planned over the next 6-7 years, not the next 2-3 years.
→The management does not foresee the need for large-scale fundraising (e.g., $50-100 million) for semaglutide or other programs.
→The focus is on improving capacity utilization and organic growth rather than immediate capital raising.
→No substantial capex or capital raising is planned for FY25; only minor capex will be undertaken to improve utilization.

Order book

Yes

→Total ongoing projects across all molecules: approximately 20 to 23.
→Added 7 confirmed contracts in the recent year (4 earlier plus 3 more in Q4).
→Focus on regulated markets with approvals expected, particularly for Teriparatide and Liraglutide pens.
→Expecting commercial supplies for Teriparatide and Liraglutide pens in the current year.
→Auto-injector projects account for 4 out of the total projects; remainder are pen injectors.
→Pipeline for new contracts remains strong with ongoing bidding for new business.
→Capacity utilization currently ~40%, expected to increase as new business ramps up.
→Expansion in contract manufacturing, including specialized devices and dry powder inhalers, mainly insulin pens.
→Total device volumes expected to grow from 11 million in FY '24 to 17-18 million in FY '25 with ~15-16% growth.

Capex plans

Yes

→No substantial capex is planned immediately; only small capexes are expected in FY25.
→Focus currently is on improving utilization of existing capacity rather than large new investments.
→A previous large capex was done last year to create infrastructure supporting up to 60-70 million devices annually.
→Installed equipment currently supports 25-30 million devices per year; additional machinery will be added as approvals and scale-up occur.
→Future additional capex of around $15-20 million may be required to expand capacity from 30 million to 70 million devices, but this is not expected within the next 2-3 years; envisioned over 6-7 years.
→Capex for semaglutide-related scale-up is expected to be lower due to location in India and existing infrastructure.
→The company is managing growth and capacity expansion prudently without aggressive capital investment in the near term.

How does Shaily Engineering Plastics Ltd rank vs peers in Consumer Durables?

Pro feature

1Shaily Engineering Plastics Ltd

Rev 3Mar 3

See full Consumer Durables sector rankings

Want more stocks like Shaily Engineering Plastics Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio